AAAI 2026: Remibrutinib & New Allergy/Asthma Treatments

The American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, held in Philadelphia from February 27 to March 2, showcased promising developments in the treatment of allergic diseases, particularly around the investigational drug remibrutinib, marketed as Rhapsido® by Novartis. Data presented suggest a potential expansion of the drug’s use beyond chronic spontaneous urticaria (CSU) into food allergies, specifically peanut allergy, offering a new avenue for those grappling with these challenging conditions.

Remibrutinib’s Expanding Profile: From Urticaria to Peanut Allergy

Novartis presented new analyses from the Phase III REMIX-1 and REMIX-2 trials, focusing on disease control and early symptom relief in patients with CSU. These findings build on the recent FDA approval of Rhapsido for CSU, reinforcing its efficacy in managing this often-debilitating condition. However, the most notable updates centered on the Phase II data evaluating remibrutinib’s safety and efficacy in treating IgE-mediated peanut allergy. This data was featured in an oral session at the AAAAI meeting, signaling a significant step forward in exploring the drug’s potential in food allergy treatment. Novartis highlighted the findings as strengthening evidence for remibrutinib as a novel treatment option for allergic and immune-mediated diseases.

According to reporting from MedPage Today, oral remibrutinib demonstrated an increase in peanut tolerance among adults with confirmed peanut allergy. This suggests the drug may help individuals consume larger amounts of peanuts without triggering an allergic reaction. The study was presented as abstract 563 at AAAAI 2026.

Understanding Bruton’s Tyrosine Kinase (BTK) Inhibition

Remibrutinib works by selectively inhibiting Bruton’s tyrosine kinase (BTK), an enzyme that plays a crucial role in the signaling pathways of immune cells. By blocking BTK, the drug aims to dampen the immune response that drives allergic reactions. This approach differs from traditional allergy treatments like epinephrine, which primarily address symptoms after they occur. BTK inhibition, in theory, could modify the underlying immune response, potentially leading to increased tolerance.

Phase III Trials on the Horizon

Novartis plans to initiate a Phase III program in food allergy (FA) in the second half of 2026. This next stage of clinical trials will be critical in confirming the efficacy and safety of remibrutinib in a larger and more diverse population. The Phase III trials will likely involve a more rigorous study design, including a placebo control group, to provide a definitive assessment of the drug’s benefits. The success of these trials will be crucial for determining whether remibrutinib can become a standard treatment option for food allergies.

What the Phase II Data Showed – and Didn’t Show

While the Phase II data presented at AAAAI 2026 are encouraging, it’s essential to understand the limitations of this early-stage research. Phase II trials are primarily designed to assess safety and identify potential efficacy signals. They are not typically powered to demonstrate definitive clinical benefit. The findings suggest remibrutinib *may* increase peanut tolerance, but further research is needed to confirm this effect and determine the optimal dosage and treatment duration. It’s also important to note that the Phase II trial focused on IgE-mediated peanut allergy, a specific type of peanut allergy, and the results may not be generalizable to other food allergies or allergy types.

Implications for Patients with Food Allergies

Food allergies affect millions of people worldwide, ranging from mild reactions to life-threatening anaphylaxis. Current management strategies primarily focus on strict avoidance of allergens and carrying emergency medication like epinephrine auto-injectors. While effective, these strategies can be burdensome and do not address the underlying immune dysregulation. Remibrutinib, if proven effective in Phase III trials, could offer a new approach to managing food allergies by potentially increasing tolerance and reducing the risk of severe reactions. However, it’s crucial to remember that remibrutinib is still an investigational therapy and is not yet available for widespread use. Patients with food allergies should continue to follow the guidance of their healthcare providers and adhere to established management plans.

The Broader Context of Food Allergy Research

The pursuit of effective food allergy treatments is an active area of research. Several other approaches are being investigated, including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and biologic therapies targeting specific immune pathways. OIT involves gradually introducing increasing amounts of the allergen to desensitize the immune system, while SLIT involves administering the allergen under the tongue. Biologic therapies, like remibrutinib, aim to modulate the immune response by targeting specific molecules involved in allergic reactions. Novartis emphasizes its commitment to addressing unmet needs in patients with immune-mediated diseases, and remibrutinib represents one piece of this broader effort.

Angelika Jahreis, Global Head of Immunology Development at Novartis, stated that the food allergy data “further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases.”

Next Steps: Monitoring the Phase III Program

The primary next step is the initiation and completion of the Phase III food allergy program planned for the latter half of 2026. Researchers will be closely monitoring the trial’s enrollment, safety data, and efficacy endpoints. Regulatory submissions to health authorities, such as the FDA, will follow successful Phase III results. The timeline for potential market availability will depend on the speed of regulatory review and approval processes. Ongoing research will also focus on identifying biomarkers that can predict which patients are most likely to respond to remibrutinib, potentially enabling a more personalized approach to treatment.